Most Undervalued Stocks 2026
Stocks trading below their intrinsic value with clear catalysts ahead. Our analysts focus on quality businesses at reasonable prices — not just low P/E stocks.
Last updated: June 2026 · For informational purposes only. Not financial advice.
We screen for stocks trading below their 5-year average P/E multiple, with at least one identifiable near-term catalyst and a balance sheet strong enough to survive a downturn. We deliberately exclude "value traps" — companies that are cheap because the business is in permanent decline.
The most undervalued blue chip on the market. Berkshire trades at ~1.4x book value with a $180B+ cash hoard — historically a signal that Buffett sees few attractive options and is building dry powder for a downturn opportunity.
Catalysts
The best bank in the world, consistently trading at a discount to its franchise value. JPMorgan generates $50B+ in annual net income and has the strongest balance sheet in US banking. Rate normalization is a tailwind.
Catalysts
Trading at a discount to peers despite owning the dominant search engine, YouTube, and Google Cloud. The market is pricing in AI search disruption risk — but Gemini integration and Cloud growth suggest Alphabet is adapting faster than feared.
Catalysts
More interest-rate-sensitive than JPM, which made 2023-24 painful. That same rate sensitivity is now a tailwind as rates normalize. BAC's massive consumer deposit base and Merrill Lynch wealth platform are underappreciated assets.
Catalysts
Energy majors are still trading as if the energy transition has already ended oil demand. ExxonMobil's Pioneer acquisition added Permian Basin scale that competes with shale growth at ~$35/barrel breakeven.
Catalysts
Chevron's balance sheet is one of the strongest in Big Oil — net debt is minimal and the buyback program is aggressive. The Hess acquisition adds significant deepwater Guyana exposure, a world-class low-cost asset.
Catalysts
The highest-risk pick on this list, but the potential upside is significant. Intel's foundry business is years behind TSMC, but the US government's CHIPS Act incentives and data center AI chip roadmap (Gaudi) give it a realistic path to relevance.
Catalysts
Keytruda (pembrolizumab) is the world's best-selling oncology drug, yet Merck trades at a meaningful discount to pharma peers. The market is overly fixated on Keytruda's 2028 patent cliff — Merck has a deep pipeline to offset it.
Catalysts
Screen stocks by P/E, growth, and fundamentals
Open Stock Screener →Valuations change daily. These rankings represent our editorial view at the time of publication.